Tscan Therapeutics is trading 6.23% up at $0.39, recovering modestly after the sharp selloff that followed its September 2, 2026 announcement.
- The company paused Phase 3 ALLOHA-2 enrollment because of insufficient capital, announced a strategic reorganization and approximately 75% workforce reduction.
- A September 3, 2026 Wedbush downgrade to Neutral added pressure.
- No new positive company-specific catalyst clearly explains the September 4 rebound.